Temozolomide for aggressive pituitary tumors
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study looks back at patients with aggressive pituitary tumors who were treated with temozolomide, a chemotherapy drug. The goal is to see how well the drug worked and to gather more information to help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a pituitary tumor that is aggressive, meaning it is growing quickly, has spread, or has not responded to standard treatments like surgery or radiation.
- You have been treated with temozolomide for this tumor.
- You have imaging (like MRI or CT scans) taken before and after your treatment to check the tumor's response.
- Your treatment with temozolomide started during the study period.
- You have enough medical records and imaging data for the researchers to review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new form of the chemotherapy drug temozolomide (called Amitzo) in people with aggressive brain tumors (grade III or IV gliomas). It aims to see if the drug is safe and effective, and is for patients who need treatment for a new diagnosis or for tumors that have come back after standard care.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
This study tests whether Tumor Treating Fields (a wearable electrical device placed on the scalp) combined with temozolomide can treat brainstem gliomas (tumors in key parts of the brainstem). It may help slow tumor growth and improve outcomes for adults who have already finished surgery/radiation or are otherwise ready for the next treatment step.
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
Hear when a new Pituitary Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.